BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

20 years of making ibuprofen faster

Faster processes: Ibuprofen DC 85 helps to decrease production time and to reduce costs. Designed specifically for direct compression into tablets, Ibuprofen DC 85 offers a number of benefits compared to conventional formulations. A common challenge when processing ibuprofen is the relatively low melting point: the API gradually starts to melt during processing and can stick to the machinery – meaning production must be stopped to clean the tablet punches. The active ingredient in Ibuprofen DC 85, in contrast, is coated with a layer of nanomaterial, which provides protection during manufacturing. The result is reliable fault-free tableting production with higher output rates. Furthermore, as expensive wet granulation and compaction processing steps are no longer necessary, our customers can lower production costs.

Speed of action: Ibuprofen Sodium & Racemic Ibuprofen Lysinate (RIBL) dissolve faster than conventional ibuprofen. This means they provide more rapid and effective pain relief during the first hour – so patients are back to full speed in no time.

BASF, the world leader in generic APIs, has been deploying the industry’s most eco-efficient ibuprofen manufacturing process for over 20 years.

BASF Pharma Ingredients and Services

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
FindPharma Custom Search

Click here